There are several trials studying the use of other ICIs in the adjuvant setting for localized ccRCC that are underway, including dual ICI regimens (PD-1 or PD-L1 inhibitor in combination with a CTLA-4 inhibitor). The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.